SCHEMBL5374807

SCHEMBL5374807

O=C1NC(Cc2ccco2)C(=O)NC1Cc1ccc(OCc2ccccc2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HTM Q9NXG6 1/20 0.41
AKT1 P31749 1/20 0.38
MAOA P21397 3/20 0.37
MAOB P27338 3/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
KDM4C Q9H3R0 1/20 0.37
ALDH1A1 P00352 2/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
USP2 O75604 1/20 0.37
HPGD P15428 1/20 0.37
HSD17B10 Q99714 1/20 0.37
POLB P06746 1/20 0.37
SGMS2 Q8NHU3 1/20 0.36
NPC1 O15118 2/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA3 P07451 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4658615 0.89 P4HTM (0.50) P4HTMMAOAMAOBMEN1KMT2A
SCHEMBL5376202 0.86 P4HTM (0.48) P4HTMMAOAMAOBMEN1KMT2A
SCHEMBL5375510 0.84 HRH3 (0.50) P4HTMMAOBMEN1KMT2AKDM4C
SCHEMBL5379438 0.81 LMNA (0.48) P4HTMMEN1KMT2AKDM4CMAPT
SCHEMBL5380505 0.80 HSD17B10 (0.42) P4HTMMAOAMAOBMEN1KMT2A
SCHEMBL5379659 0.80 EGFR (0.44) P4HTMMAOAMAOBMEN1KMT2A
SCHEMBL5392310 0.80 MMP1 (0.47) P4HTMMAOBMEN1KMT2AKDM4C
SCHEMBL5381466 0.80 MAPK1 (0.46) P4HTMMEN1KMT2AMAPTTNKS2
SCHEMBL5374989 0.80 HRH3 (0.44) P4HTMMAOAMAOBMEN1KMT2A
SCHEMBL14400075 0.75 HRH3 (0.50) KMT2AKDM4CUSP2POLBHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288545-B2 Piperazinedione compounds ANGIORX CORPORATION (TW) 2007-10-30 US disclosed
US-7288545-B2 Piperazinedione compounds ANGIORX CORPORATION (TW) 2007-10-30 US disclosed
US-20040132738-A1 Piperazinedione compounds ANGIORX CORPORATION (TW) 2004-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132738-A1 Piperazinedione compounds CBR1, KDR, FLT1 P4HTM 1191/4885AKT1 3148/4885MAOA 851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.